LUND, Sweden, Aug. 14, 2019 /PRNewswire/ -- BioInvent International AB (OMXS: BINV) will issue its interim report for the second quarter 2019 on Thursday August 22 at 8.30 a.m. CEST, followed by an audiocast with teleconference at 11.00 a.m. CEST, hosted by Martin Welschof, CEO and members of the management team. The presentation will be held in English.
To participate, please call any of the following phone numbers from:
Sweden: +46-8-566-426-92
UK: +44-333-300-9272
US: +1-833-526-8383
Webcast: https://tv.streamfabriken.com/bioinvent-q2-2019
About BioInvent
BioInvent International AB (OMXS: BINV) is focused on the discovery and development of novel and first-in-class immuno-modulatory antibodies to treat cancer. The Company's lead program BI-1206, is currently in Phase l/ll for non-Hodgkin lymphoma and chronic lymphatic leukemia. BioInvent's pre-clinical portfolio is focused on targeting key immune suppressive cells and pathways of the tumor microenvironment, including regulatory T cells, tumor-associated myeloid cells and mechanisms of antibody drug-resistance. The Company has a strategic research collaboration with Pfizer Inc., and partnerships with Transgene, Bayer Pharma, Daiichi Sankyo, and Mitsubishi Tanabe Pharma. BioInvent generates near term revenues from its fully integrated manufacturing unit producing antibodies for third parties for research through to late-stage clinical trials. More information is available at www.bioinvent.com.
Martin Welschof, CEO
+46(0)46-286-85-50
martin.welschof@bioinvent.com
Hans Herklots, LifeSci Advisors
+41-79-598-71-49
hherklots@lifesciadvisors.com
BioInvent International AB (publ)
Co. Reg. No. Org nr: 556537-7263
Visiting address: Sölvegatan 41
Mailing address: 223 70 LUND
Phone: +46 (0)46-286-85-50
www.bioinvent.com
This information was brought to you by Cision http://news.cision.com
The following files are available for download:
https://mb.cision.com/Main/583/2880881/1089937.pdf | Press release (PDF) |
